Triptolide inhibits amyloid-β production and protects neural cells by inhibiting CXCR2 activity

Ju Wang1, Zi-Qi Shi, Xiaojun Xu

  • 1Department of Pharmacognosy, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.

Insights

Triptolide, a natural compound, protects neurons by inhibiting CXCR2 and reducing amyloid-beta production. This neuroprotective effect is linked to its ability to block CXCR2 activity.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Natural Products Chemistry

Background:

  • Inflammation-mediated neuronal damage is a key factor in neurodegenerative diseases.
  • Tripterygium wilfordii yields triptolide, a compound with known biological activities.
  • The specific mechanisms underlying triptolide's neuroprotective effects require further elucidation.

Purpose of the Study:

  • To investigate the neuroprotective mechanisms of triptolide.
  • To determine the effect of triptolide on CXCR2 and presenilin expression in neuronal cells.
  • To evaluate the impact of triptolide on amyloid-beta production and neuronal cytotoxicity.

Main Methods:

  • Utilized neuroblastoma cell line SHSY5Ysw and HEK293sw cells.
  • Assessed the expression of CXCR2 and presenilin.
  • Measured amyloid-beta 1-42 production using IC50 values.
  • Examined the protection of primary cortical neurons against CXCL1-induced cytotoxicity.

Main Results:

  • Triptolide inhibited the expression of CXCR2 and presenilin in SHSY5Ysw cells.
  • Triptolide potently inhibited amyloid-beta 1-42 production with low IC50 values (30 pM in HEK293sw, 2 nM in SHSY5Ysw).
  • Triptolide demonstrated neuroprotective effects by preventing primary cortical neurons from chemokine CXCL1-induced damage.

Conclusions:

  • Triptolide exhibits significant neuroprotective properties.
  • The inhibition of CXCR2 activity is a primary mechanism for triptolide's neuroprotective effects.
  • Triptolide's ability to reduce amyloid-beta production and protect neurons from inflammatory damage suggests therapeutic potential.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...